Literature DB >> 10341303

Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.

X M Zeng1, G P Martin, S K Tee, A A Ghoush, C Marriott.   

Abstract

Ternary mixtures composed of coarse lactose (CL) (90.8 microm), salbutamol sulphate (SS) (5.8 microm) and either micronised lactose (ML) (5 microm) or intermediate sized lactose (IML) (15.9 microm) in a ratio of 66.5:1:1 w/w were prepared using different mixing sequences of the various components. In addition, a binary mixture composed of CL and SS (67.5:1 w/w) was also prepared as the control. The in vitro deposition of SS was measured using a twin stage impinger after aerosolisation at 60 and 90 l min-1 via a Rotahaler. The aerodynamic particle size distribution of both the aerosolised SS and lactose was further analysed using an Andersen cascade impactor at 60 l min-1. All ternary mixtures produced a significantly higher (analysis of variance, P<0.01) fine particle fraction (FPF) and fine particle dose (FPD) of SS than the control after aerosolisation at either 60 or 90 l min-1. Formulations containing the ML produced significantly (P<0.05) higher FPF and FPD of SS than those containing the IML at both aerosolisation flow rates. Different mixing sequences were also shown to result in different deposition profiles of both SS and lactose after aerosolisation of the ternary mixtures containing ML at 60 l min-1. The formulation prepared by first blending ML with CL before mixing with SS produced a higher FPF and FPD of SS but a lower FPF of lactose than the same formulation in terms of composition but prepared using different mixing orders of the three components. In contrast, the formulations containing IML produced a similar deposition profile to SS, regardless of the mixing sequences, and so did the formulations containing ML aerosolised at 90 l min-1. These results suggest that the effect of mixing sequences on drug deposition may become more prominent at lower aerosolisation flow rates and by reducing the size of any added fine lactose.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10341303     DOI: 10.1016/s0378-5173(99)00021-6

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  18 in total

1.  Effects of device and formulation on in vitro performance of dry powder inhalers.

Authors:  Wallace P Adams; Sau L Lee; Robert Plourde; Robert A Lionberger; Craig M Bertha; William H Doub; Jean-Marc Bovet; Anthony J Hickey
Journal:  AAPS J       Date:  2012-04-05       Impact factor: 4.009

2.  Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

Authors:  V N P Le; T H Hoang Thi; E Robins; M P Flament
Journal:  AAPS PharmSciTech       Date:  2012-03-08       Impact factor: 3.246

3.  Micronization of a soft material: air-jet and micro-ball milling.

Authors:  Imran Y Saleem; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2010-11-24       Impact factor: 3.246

4.  The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.

Authors:  Philippe Begat; David A V Morton; John N Staniforth; Robert Price
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

Review 5.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

6.  An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.

Authors:  Matthew D Jones; Jennifer C Hooton; Michelle L Dawson; Alan R Ferrie; Robert Price
Journal:  Pharm Res       Date:  2007-10-19       Impact factor: 4.200

7.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

8.  An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.

Authors:  Hanne Kinnunen; Gerald Hebbink; Harry Peters; Jagdeep Shur; Robert Price
Journal:  AAPS PharmSciTech       Date:  2014-04-23       Impact factor: 3.246

9.  Theophylline cocrystals prepared by spray drying: physicochemical properties and aerosolization performance.

Authors:  Amjad Alhalaweh; Waseem Kaialy; Graham Buckton; Hardyal Gill; Ali Nokhodchi; Sitaram P Velaga
Journal:  AAPS PharmSciTech       Date:  2013-01-08       Impact factor: 3.246

10.  Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?

Authors:  Nazrul Islam; Peter Stewart; Ian Larson; Patrick Hartley
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.